Addex Therapeutics Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADXN research report →
Range $30 – $30
Price Chart
About the company
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction.
- CEO
- Timothy Mark Dyer
- IPO
- 2020
- Employees
- 3
- HQ
- Geneva, GE, CH
Get TickerSpark's AI analysis on ADXN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.27M
- P/E
- -0.51
- PEG
- -0.02
- P/S
- 47.99
- P/B
- 2.18
- EV/EBITDA
- -0.68
- Div Yield
- 0.00%
- Gross Margin
- 41.19%
- Op Margin
- -4115.07%
- Net Margin
- -10874.58%
- ROE
- -172.76%
- ROIC
- -120.01%
Latest fiscal year · YoY change
- Revenue
- $29.97K-92.6%
- Gross Profit
- $29.97K-92.6%
- Op Income
- $-2,814,598
- Net Income
- $-6,728,246-195.4%
- EPS
- $-6.88-181.9%
- OCF Growth
- +61.4%
- FCF Growth
- +61.4%
- 52W High
- $10.43
- 52W Low
- $2.56
- 50D MA
- $3.18
- 200D MA
- $5.46
- Beta
- 2.07
- RSI (14)
- 52
- Avg Volume
- 383.35K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Addex said it strengthened its balance sheet, regained full rights to its GABAB PAM platform, and is advancing SUD and cough programs while continuing to rely on partnerships or financing to move assets into the clinic.· September 28, 2026
- Raised $2.8 million through the ATM and said cash runway extends into Q4 2027.
- Regained rights to the GABAB PAM program from Indivior, giving Addex full freedom to develop multiple candidates and seek partners.
- Lead GABAB-PAM candidate for substance use disorder is ready for IND filing; cough program has completed pre-IND work and is ready to start IND-enabling studies subject to financing.
- Neurosterix, in which Addex owns 20%, is advancing NTX-253 and expects phase I data in Q4 this year.
- H1 operating loss improved slightly to CHF 1.1 million from CHF 1.3 million, while net loss was stable at about CHF 3.4 million.
Addex reported H1 2026 operating loss of CHF 1.1 million, versus CHF 1.3 million in H1 2025, helped by lower outsourced R&D on the GABAB PAM program. Net loss was stable at around CHF 3.4 million in both H1 2026 and H1 2025. The company ended June 30, 2026 with CHF 0.8 million in cash, down from CHF 1.6 million at December 31, 2025, and said it raised $2.8 million through its ATM facility in Q3, which provides runway into Q4 2027. On guidance, management said the SUD candidate is ready for IND filing, the cough program’s IND-enabling studies are ready to start subject to financing, and Neurosterix expects phase I data for NTX-253 in Q4 this year.
Tim Dyer framed the quarter around strategic value creation rather than near-term revenue, emphasizing the ATM raise, regained GABAB rights, and Addex’s continued ownership of 20% of Neurosterix. He described the Indivior termination as a positive because it returns full freedom to develop the platform and broadens partnering options across multiple indications. His tone was constructive and opportunistic, with repeated references to finding the right capital structure and partners to advance the portfolio.
Dyer’s financial commentary focused on a modest reduction in operating loss to CHF 1.1 million from CHF 1.3 million, which he attributed mainly to lower outsourced R&D. He said Addex used CHF 1.2 million in operations during the six-month period and received CHF 0.4 million from treasury ADS sales, ending with CHF 0.8 million in cash. He also highlighted the $2.8 million ATM raise and reiterated that this extends runway into Q4 2027, while current liabilities were CHF 1.4 million and non-current liabilities CHF 0.2 million.
Analysts focused on the patent estate around the reacquired Indivior-related compounds and the strategic path for unlocking value. Management said five patents were filed in 2024, two were licensed to Indivior and have come back, and the expected expiration date, if granted, is 2044. Dyer also said Addex filed and managed the patents itself, none were joint patents, and the company is considering both partnerships and a possible spin-out, but first wants to secure capital to move the programs forward.
The strongest bull case from this call is that Addex now controls a broader GABAB PAM platform with multiple candidates and indications, after regaining rights from Indivior. Management also pointed to a long-dated patent position, a ready-to-file SUD candidate, and a cough asset with preclinical data suggesting a therapeutic margin versus sedative effects. The $2.8 million ATM raise extends runway into Q4 2027, giving the company more time to pursue partners or a spin-out strategy.
The main risk is financing: the company said cough IND-enabling studies are ready to start only subject to securing financing, and the broader portfolio still needs capital to advance. Addex ended the period with just CHF 0.8 million in cash before the ATM proceeds, underscoring limited standalone resources. There is also no clinical-stage revenue-producing asset yet at Addex itself, so value depends on successful development, partnering, or monetization of the reacquired programs.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 0.0%
- Shares Outstanding
- 1.23M
- Float Shares
- 32
of shares held by institutions
3 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Hill Raymond George | other | 1,319,996 |
| Nov 11, 26 | Lawton Vincent Michael | other | 1,885,708 |
| Nov 11, 26 | Lawton Vincent Michael | other | 942,854 |
| Nov 11, 26 | Mills Roger | other | 942,854 |
| Nov 11, 26 | Hill Raymond George | other | 942,854 |
| Nov 11, 26 | Teyssedou Lenaic Nathanael | other | 3,771,415 |
| Nov 11, 26 | Nunn Jason Raleigh | other | 942,854 |
| Nov 11, 26 | Manke Isaac | other | 942,854 |
| Nov 11, 26 | Dyer Timothy Mark | other | 18,857,075 |
| Sep 2, 26 | Teyssedou Lenaic Nathanael | other | 100,485 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ADXN coverage
Recent articles, reports, and earnings notes.
No research on ADXN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADXN report →ADDEX THERAPEUTICS TO REPORT 2026 THIRD QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 25, 2026
globenewswire.com · Nov 20
Addex Spin-out Neurosterix Closes $105 Million Series B Financing
globenewswire.com · Nov 11
ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES
globenewswire.com · Oct 29
Reviewing Addex Therapeutics (NASDAQ:ADXN) & Clene (NASDAQ:CLNN)
defenseworld.net · Oct 19
Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage
defenseworld.net · Oct 10
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
globenewswire.com · Oct 8
Addex Therapeutics Announces Executive Management Changes
globenewswire.com · Oct 2
What Addex Therapeutics (ADXN) Said on Its Q2 Earnings Call
defenseworld.net · Sep 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.